genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces it will release its interim results for the six months ended 31 December 2021 on Tuesday, 29 March 2022.
Genedrive PLC (GDR.L) UK CTDA application for Genedrive® COV19-ID kit
Sensitivity and specificity data submitted meets MHRA requirements
Genedrive PLC (GDR.L) CE-IVD certification for Point-of-Care Genedrive®COV19-ID kit
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that further to the announcement of 29 November 2021, its rapid point of care Genedrive®COV19-ID Kit has received CE-IVD
Genedrive PLC (GDR.L) POC kit submitted for CE-IVD certification
Point-of-care Genedrive®COV19-ID submitted for CE-IVD certification Sets new benchmark in speed, accuracy and ease of use
Genedrive PLC (GDR.L) Audited Final Results
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces its audited Final Results for the year ended 30 June 2021.
Genedrive PLC (GDR.L) Result of Open Offer
London, UK – 29 September 2021: genedrive plc (LSE: GDR), the near-patient molecular diagnostics company, announces that it has conditionally raised total gross proceeds of approximately £1.1 million through the
Genedrive PLC (GDR.L) New Genedrive system readied for AIHL launch
New Genedrive® system readied for Antibiotic Induced Hearing Loss launch
Genedrive PLC (GDR.L) Genedrive® COVID-19 Point of Care device update
genedrive plc (AIM: GDR), the near-patient molecular diagnostics company, provides an update on the development of its Genedrive® COV19-ID Kit, a rapid Point of Care (PoC) molecular test for SARS-CoV-2
Genedrive PLC (GDR.L) COVID-19 PCR test approved by Indian regulator
Genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that the Genedrive® 96 SARS-CoV-2 Kit has been formally approved by the Indian Council of Medical Research (“ICMR”).
Genedrive PLC (GDR.L) Excellent performance data for Genedrive® HCV test
Excellent performance of Genedrive®HCV -ID Kit in large multi-centre study
Genedrive PLC (GDR.L) PHE National Framework Agreement
Genedrive successful in PHE National Framework Agreement for Diagnostics Goods and Services